Thrombolysis of stroke mimics via telestroke

Vivien H Lee, Ravyn Howell, Randheer Yadav, Sharon Heaton, Karen L Wiles, Sushil Lakhani

ABSTRACT
Background The rate of intravenous tissue plasminogen activator (IVtPA) administered to stroke mimics (SM) occurs in 24%–44% of telestroke series.
Methods We reviewed 270 suspected acute ischaemic stroke (AIS) patients who were evaluated by telestroke and received IVtPA from 1 July 2016 to 30 September 2017 at our academic comprehensive stroke centre.
Results Among 270 AIS patients who received IVPA via telestroke, 64 (23.7%) were diagnosed with SM. Compared with patients who had a stroke, the SM group was younger (mean age 56.4 vs 68.2, p<0.0001), more likely to be female (60.9% vs 45.6%, p=0.0324) and had longer door-to-needle times (85.3 vs 69.9, p=0.0008). The most common SM diagnoses were migraine 26 (40.6%), conversion disorder 12 (18.8%), encephalopathy 7 (10.9%) and unmasking (9.4%). Among the SM, migraine and conversion disorder were younger compared with the other subgroups (p<0.001). Functional exam elements were noted more frequently in conversion disorder (66.7%) and migraine (34.6%), but rare in other diagnoses (p=0.006). Among the SM, 23 (35.9%) had a history of a prior similar episodes, and 15 (23.4%) had a history of 5 or more. Conclusions In our telestroke programme, 23.7% of those administered thrombolysis had a final diagnosis of SM.

INTRODUCTION
The implementation of telestroke has increased the use of intravenous tissue plasminogen activator (IVtPA) at community hospitals by allowing access to stroke expertise remotely and has gained increasingly widespread acceptance. The rate of stroke mimics (SM) in telestroke cohorts is reported to be 24%–44% in large series, although the rate at which SM subsequently go on to receive thrombolysis is not well described in telestroke cohorts.1 The aim of this study was to describe the frequency and characteristics of SM evaluated by telestroke.

METHODS
We performed a retrospective review of suspected acute ischaemic stroke (AIS) patients who were evaluated by telestroke and received IVtPA from 1 July 2016 to 30 September 2017. Our academic comprehensive stroke programme includes 26 telestroke emergency rooms (ER) throughout Ohio. Our telestroke platform does not allow access to the electronic medical records (EMR) of outside hospital. During the time period of the study, nearly all patients who received IVtPA at the outside hospital ERs were transferred to the hub for post IVtPA care. The standard protocol was that telestroke consult was initiated for suspected AIS patients within 8-hour window from time of last known normal. The telestroke physician would ‘beam in’ via high-quality bidirectional audiovisual format for history and exam and with access to review neuroimaging. IVtPA cases with a negative diffusion-weighted images (DWI) were reviewed by study vascular neurologist (VHL) to confirm diagnosis. All final diagnosis was made clinically by study vascular neurologist (VHL) after reviewing clinical teams impression and diagnostic workup. If DWI showed infarct, these were automatically categorised as stroke. If DWI was negative, these were categorised as SM if an alternative diagnosis was considered clinically more likely, otherwise they were categorised as TIA. Data was collected on demographics, medical history, symptoms, door-to-needle time (DTN) initial National Institutes of Health Stroke Scale (NIHSS), functional embellishment, vital signs and neuroimaging results. Symptomatic intracerebral haemorrhage (sICH) was defined as radiographic haemorrhage accompanied by ≥4 point worsening in the NIHSS. Telestroke mimic (TM) score was calculated per the described nomogram.1 Statistical analyses were performed using JMP software package (V.14). Univariate analysis was performed with \( \chi^2 \) test and Fisher’s exact test as appropriate. All tests were two sided, and a p value was considered significant at <0.05.

Data availability
Anonymised data will be shared on request from any qualified investigator.

RESULTS
Among 270 suspected AIS patients who received IVtPA via telestroke, the mean age was 65.4 (range 21–95) and 133 (49.3%) were female.
Among 239 (88.1%) with MRI brain DWI completed, 156 (57.8%) were DWI+ and 83 (30.7%) were DWI negative. The majority 147 (54.4%) of IVtPA cases were administered at the top four highest volume spoke ERs. Among 270 patients who received IVtPA for possible AIS via telestroke, we identified 64 (23.7%) with final diagnosis of SM (figure 1).

Compared with AIS patients, the SM group was younger (mean age 56.4 vs 68.2, p<0.0001), more likely to be female (60.9% vs 45.6%, p=0.0324), have longer DTN times (85.3 vs 69.9 min, p=0.0008), and longer door to tPA recommend times (65.0 vs 53.2 min, p=0.0034). SM patients did not differ from stroke patients in terms of initial NIHSS, initial systolic blood pressure or weight.

The SM diagnoses seen were migraine 26 (40.6%), conversion 12 (18.8%), encephalopathy 7 (10.9%), unmasking (9.4%) and other 13 (20.3). Other diagnoses include hyperglycaemic (3), hypoglycaemic (1), seizures (3), neoplasm (1), tongue swelling (1) spinal cord (1), syncope (1), vitreous haemorrhage (1) and peripheral nerve (1). Among the SM, 59 (92.2%) had negative DWI, and among patients without DWI, all five had negative CT brain angiogram and four had negative CT brain perfusion. No sICH was observed in the SM group. Among the SM, there were differences between the aetiologies (table 1).

Mean age was younger for migraine (52.0) and conversion (49.6) compared with the other subgroups (p<0.0001). Functional elements were noted on exam more frequently in conversion (66.7%) and migraine (34.6%), but rare in other diagnoses (p=0.0018). Among SM, the mean TM score was 14.4, (range 4.5–29.9), and only 3 (4.7%) of SM had a TM score ≤5. TM score ≥20 was seen in 8 (12.5%). Among SM, 23 (35.9%) had a history of a prior similar episode, and 15 (23.4%) had a history of more than 5. Eight (12.5%) would present with a similar recurrent episode, with two patients receiving IVtPA again in the future (1 conversion and 1 migraine).

**Table 1** Stroke mimic patients

<table>
<thead>
<tr>
<th></th>
<th>Migraine (26)</th>
<th>Conversion (12)</th>
<th>Encephalopathy (7)</th>
<th>Unmasking (6)</th>
<th>Other (13)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean)</td>
<td>52.0</td>
<td>49.6</td>
<td>79.4</td>
<td>56.3</td>
<td>59.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex (Female)</td>
<td>19 (73.0%)</td>
<td>7 (58.3%)</td>
<td>5 (71.4%)</td>
<td>3 (50.0%)</td>
<td>5 (38.5%)</td>
<td>0.2844</td>
</tr>
<tr>
<td>Mean DTN (minutes)</td>
<td>95.9</td>
<td>84.1</td>
<td>79.7</td>
<td>70.2</td>
<td>74.8</td>
<td>0.5346</td>
</tr>
<tr>
<td>Mean systolic blood pressure (mm Hg)</td>
<td>143.0</td>
<td>141.9</td>
<td>160.7</td>
<td>120.5</td>
<td>168.1</td>
<td>0.0037</td>
</tr>
<tr>
<td>NIHSS</td>
<td>6.3</td>
<td>7.8</td>
<td>8.7</td>
<td>7.0</td>
<td>9.8</td>
<td>0.2729</td>
</tr>
<tr>
<td>Headache</td>
<td>21 (80.8%)</td>
<td>3 (25%)</td>
<td>1 (14.3%)</td>
<td>1 (16.7%)</td>
<td>1 (7.7%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>History of migraine</td>
<td>11 (42.3%)</td>
<td>5 (41.7%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.0004</td>
</tr>
<tr>
<td>Hypertension</td>
<td>17 (65.4%)</td>
<td>5 (41.7%)</td>
<td>5 (71.4%)</td>
<td>5 (83.3%)</td>
<td>10 (76.9%)</td>
<td>0.3199</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>15 (57.7%)</td>
<td>1 (8.3%)</td>
<td>4 (57.1%)</td>
<td>2 (33.3%)</td>
<td>6 (46.2%)</td>
<td>0.0362</td>
</tr>
<tr>
<td>Functional exam</td>
<td>8 (30.8%)</td>
<td>8 (66.7%)</td>
<td>0</td>
<td>0</td>
<td>1 (7.8%)</td>
<td>0.0006</td>
</tr>
<tr>
<td>Prior episodes (&gt;5)</td>
<td>7 (26.9%)</td>
<td>5 (41.7%)</td>
<td>1 (14.3%)</td>
<td>1 (16.7%)</td>
<td>1 (7.7%)</td>
<td>0.2969</td>
</tr>
<tr>
<td>Discharge home</td>
<td>26 (100%)</td>
<td>10 (83.3%)</td>
<td>4 (57.1%)</td>
<td>4 (66.7%)</td>
<td>8 (61.5%)</td>
<td>0 0.012</td>
</tr>
</tbody>
</table>

DTN, door to needle; NIHSS, National Institutes of Health Stroke Scale.
but how often SM inadvertently go on to receive thrombolysis is less clear. The rate of SM in thrombolysis series reported is highly variable, likely due to under-reporting bias with retrospective series, which report rates as low as 1.8% and as high as 14%. In a GWTG (Get With The Guidelines) retrospective registry cohort, 3.5% of tPA treatments were given to SM, but as SM inclusion in the registry was optional for stroke centres, there is likely significant under-reporting bias that has to be taken into account. In prospective studies, rates of SM in thrombolytic cohorts are much higher. In a 5-year prospective study, 75/516 (14.5%) of tIVPA patients were SM. In the NOR-TEST (The Norwegian Tenecteplase Stroke Trial 2) trial, which was a tenecteplase phase 3 trial, 181 (16.6%) of 1091 randomised patients were SM, with migraine being the most frequent SM diagnosis.

Saver suggested an acceptable rate of SM at 3%, but acknowledged that the calculus for risk–benefit favours the ‘quickdraw’ approach for tIVPA, especially given that the rate of sICH in SM is exceedingly low. However, increasing diagnostic certainty for AIS likely delays DTN times and may increase the risk of missed thrombolysis. Many thrombolysis series confirm an exceedingly low rate of sICH in SM of 0%–0.5%. In fact, the most recent AHA guidelines in 2019 recognise this and specifically recommend thrombolysis to SM given the low rate of sICH and state that starting tIVPA is preferred over delaying treatment to pursue additional diagnostic studies. The acute stroke protocol for our telestroke network requires only a non-contrast CT brain for thrombolysis decision, and we do not delay thrombolysis decision to pursue advanced neuroimaging, which may explain the higher rate of SM in our thrombolysis cohort. However, the alternative of erring on the side of excluding patients with a suspected diagnosis of SM may also lead to a greater overall of missed diagnosis of stroke which would increase withholding of time-sensitive treatment for otherwise eligible patients. A study of certified stroke programmes showed 22% of AIS are initially misdiagnosed with 33% of missed stroke cases presenting within 3 hours, and in 35% the diagnosis was still missed even after being seen early by neurology in the ER. This suggests that the risk of missing a true stroke diagnosis and withholding tIVPA is a greater concern than the risk of giving tIVPA to SM.

The TM score has been validated in external cohorts, and an operational cut-off of ≤5 has been suggested as indicative of SM (65% chance based on the score). In our series, TM score ≤5 was seen in only 4.7% of SM, and therefore, its real-world usefulness appears limited. In our series, the lack of ability to see EMR of the outside hospital contributed to thrombolysis in SM, as similar prior episodes and work-up was not visible to the telestroke physician. There may also be limitations on detecting nuances of the physical exam for SM remotely.

A reasonable correlate to tIVPA clinical decision making for suspected SM is appendicitis, where clinicians err on the side of over-treatment to avoid missing true surgical cases. A negative appendectomy rate (i.e., the portion of patients with suspected appendicitis clinically with normal appendices removed surgically) of 25% has been acceptable historically. In other clinical situations where one must balance missing a true diagnosis (and potential treatment window) versus potentially overtreating false positives, there is the acceptance of overtreatment. It has been demonstrated that improvements in the efficiency of tIVPA delivery (i.e., decreasing DTN times) are associated with increased rates of SM thrombolysis rates. Balancing the rate of inadvertent thrombolysis of SM against the rate of undertreatment of true AIS means recognising that decreasing the former likely increases the latter. Given the differences of telemedicine compared with bedside evaluation, we suggest that compared with in-person evaluation, the proposed goal of a 3% rate of SM thrombolysis is unreasonable and centres that achieve this rate are likely undertreating or missing eligible stroke patients or delaying treatment in order to increase certainty of stroke diagnosis. In our telestroke series, 23.7% of patients who received thrombolysis were diagnosed with SM, which aligns with a high rate of SM presentations in telestroke cohorts of up to 44% and is slightly higher than a prospective bedside in person thrombolysis study showing 16.6% rate of SM. A higher SM thrombolysis rate for telestroke compared with the bedside rate should be acceptable, and similar to the accepted negative appendectomy rate, we suggest a reasonable goal of 25%.

The strength of our study is that all patients were evaluated and examined by stroke neurologists on presentation and the final diagnosis was determined by stroke neurologist. Also, as we used our telestroke database, this included all patients given tIVPA in our telestroke network, whereas since these patients would not have coded out as stroke, our GWTG registry would have not included these patients as SM reporting is optional). Limitations of our study include the fact that our telestroke platform allows only access to view imaging, but does not allow access to the all the stroke hospitals EMR. Our study shares inherent limitations associated with a retrospective review.

CONCLUSION
In our academic tertiary referral telestroke programme, 23.7% of patients administered thrombolysis had a final diagnosis of SM. We suggest that a reasonable SM thrombolysis rate for telestroke programme should be one in four, similar to the accepted negative appendectomy rate, as that the risk of overtreatment should be accepted over the risk of undertreatment.

Twitter Vivien H Lee @VivienHLee

Contributors All authors have contributed to this manuscript, including data collection, writing the manuscript, and significant editing and revision of manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.
Ethics approval This study was approved by This project was approved by IRB 2017E0620. As this was a retrospective chart review with no patient contact, IRB granted us HIPAA waiver.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Vivien H Lee http://orcid.org/0000-0002-8615-198X

REFERENCES